Recrutamento encerrado
FASE
Número Europeu 2021-005034-42
MK-7684A-008 KEYVIBE-008
A Phase 3, Randomized, Double-Blind Study of MK-7684A in Combination With Etoposide and Platinum Followed by MK-7684A vs Atezolizumab in Combination With Etoposide and Platinum Followed by Atezolizumab for the First-Line Treatment of Participants With Extensive-Stage Small Cell Lung Cancer
Detalhes
Destaques